{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:24Z","timestamp":1791245184937,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104880","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:40:18Z","timestamp":1784590818000},"page":"104880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cardiotoxicity of newer HER2-Directed therapies in breast cancer: A systematic review and meta-analysis of incidence and comparative risk"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-6773","authenticated-orcid":false,"given":"Senthamizhan","family":"Sundaramoorthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2567-5955","authenticated-orcid":false,"given":"Narendhar","family":"Gokulanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5398-3221","authenticated-orcid":false,"given":"Rona","family":"Joseph P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-5253","authenticated-orcid":false,"given":"Anoop","family":"Tm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5581-3509","authenticated-orcid":false,"given":"Sherin P.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7717-0003","authenticated-orcid":false,"given":"Harpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2236-9891","authenticated-orcid":false,"given":"Thamizharuvi","family":"Muthukumarasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5419-2019","authenticated-orcid":false,"given":"Kalai Bharathi","family":"Jayaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1858-4027","authenticated-orcid":false,"given":"Parvathy","family":"Rajmohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyshak","family":"Thovarayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-744X","authenticated-orcid":false,"given":"Aswin","family":"Sathyadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4965-8012","authenticated-orcid":false,"given":"Shibu V.","family":"Ignatious","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sariga Ajit","family":"Valaparambil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104880_bib1","series-title":"Breast cancer [Internet]","year":"2025"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib2","article-title":"Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2026.104880_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2025.103168","article-title":"HER2-Targeted therapies and cardiotoxicity: from major concern to manageable risk","author":"Pamungkas","year":"2025","journal-title":"Curr Probl Cardiol"},{"issue":"11","key":"10.1016\/j.breast.2026.104880_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104880_bib5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrclinonc.2009.216","article-title":"Molecular predictors of response to trastuzumab and lapatinib in breast cancer","volume":"7","author":"Esteva","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104880_bib6","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib7","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.14694\/EdBook_AM.2015.35.e117","article-title":"What can we learn about antibody-drug conjugates from the T-DM1 experience?","volume":"35","author":"Esteva","year":"2015","journal-title":"AAm Soc Clin Oncol Educ Book"},{"issue":"10191","key":"10.1016\/j.breast.2026.104880_bib8","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.breast.2026.104880_bib9","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1001\/jamaoncol.2020.4749","article-title":"Early trastuzumab interruption and recurrence-free survival in ERBB2-positive breast cancer","volume":"6","author":"Copeland-Halperin","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104880_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2018.12.022","article-title":"Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1","volume":"109","author":"Montemurro","year":"2019","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.breast.2026.104880_bib11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104880_bib12","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"bmj"},{"key":"10.1016\/j.breast.2026.104880_bib13","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.breast.2026.104880_bib14","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.breast.2026.104880_bib15","first-page":"1","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","author":"McGuinness","year":"2020","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.breast.2026.104880_bib16","series-title":"Doing meta-analysis with R: a Hands-On guide","author":"Harrer","year":"2021"},{"key":"10.1016\/j.breast.2026.104880_bib17","series-title":"GRADE handbook for grading quality of evidence and strength of recommendations","year":"2013"},{"key":"10.1016\/j.breast.2026.104880_bib18","series-title":"Cochrane handbook for systematic reviews of interventions","article-title":"Chapter 11: presenting results and \u201csummary of findings\u201d tables","author":"Sch\u00fcnemann","year":"2011"},{"key":"10.1016\/j.breast.2026.104880_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.breast.2022.05.004","article-title":"Long term outcome data from the EORTC 75111-10114 ETF\/BCG randomized phase II study: pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression","volume":"64","author":"Wildiers","year":"2022","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.breast.2026.104880_bib20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JCO.21.02937","article-title":"Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial","volume":"41","author":"Rugo","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104880_bib21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10549-020-05728-w","article-title":"Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study","volume":"182","author":"Xu","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.breast.2026.104880_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103938","article-title":"Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06\/NCCTG N063D (Alliance)]","volume":"9","author":"de Azambuja","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100772","article-title":"Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial","volume":"8","author":"de Azambuja","year":"2023","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.breast.2026.104880_bib24","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","article-title":"Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial","volume":"7","author":"van der Voort","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104880_bib25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"Von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.breast.2026.104880_bib27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib28","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/s41467-024-45591-7","article-title":"Neoadjuvant\u2013adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial","volume":"15","author":"Huang","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.breast.2026.104880_bib29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00280-013-2279-6","article-title":"Exposure\u2013response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters","volume":"72","author":"Garg","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"27","key":"10.1016\/j.breast.2026.104880_bib30","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with\u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104880_bib31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"issue":"10390","key":"10.1016\/j.breast.2026.104880_bib32","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.breast.2026.104880_bib33","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.breast.2026.104880_bib34","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41523-022-00385-2","article-title":"Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial","volume":"8","author":"Barroso-Sousa","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.breast.2026.104880_bib36","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.21.00896","article-title":"Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2\u2013positive early breast cancer: the phase III KAITLIN study","volume":"40","author":"Krop","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104880_bib38","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.breast.2026.104880_bib40","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1200\/JCO.2016.70.6267","article-title":"Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy","volume":"35","author":"Urruticoechea","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104880_bib41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","article-title":"Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study","volume":"152","author":"O'Shaughnessy","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104880_bib43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104880_bib44","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-025-02149-3","article-title":"ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"10","author":"Hu","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"issue":"9","key":"10.1016\/j.breast.2026.104880_bib46","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.breast.2026.104880_bib47","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104880_bib48","unstructured":"Xia W, Yuan Z, Wang S, Zheng Q, Wu Z, Zhong M, et al. Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: a randomized phase II study (METIS) ."},{"issue":"14","key":"10.1016\/j.breast.2026.104880_bib49","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.2014.56.9590","article-title":"Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2\u2013positive advanced breast cancer: final results of NCIC CTG MA. 31","volume":"33","author":"Gelmon","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104880_bib50","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104880_bib51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2\u2013positive, advanced breast cancer: primary results from the phase III MARIANNE study","volume":"35","author":"Perez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib52","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1093\/oncolo\/oyad160","article-title":"A phase II study of neoadjuvant PLD\/cyclophosphamide and sequential nab-Paclitaxel plus dual HER2 blockade in HER2-positive breast cancer","volume":"29","author":"Yang","year":"2024","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.breast.2026.104880_bib53","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/1078-0432.CCR-07-4636","article-title":"Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2\u2013positive metastatic breast cancer","volume":"14","author":"Portera","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10637-020-00991-6","article-title":"Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2\u2013positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)","volume":"39","author":"Yamashita","year":"2021","journal-title":"Invest N Drugs"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12916-018-1233-1","article-title":"Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial","volume":"17","author":"Gavil\u00e1","year":"2019","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s43044-023-00331-y","article-title":"Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer","volume":"75","author":"Levicki","year":"2023","journal-title":"Egypt Heart J"},{"issue":"22","key":"10.1016\/j.breast.2026.104880_bib57","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1002\/cncr.28284","article-title":"Long\u2010term cardiac safety and outcomes of dose\u2010dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer","volume":"119","author":"Morris","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.breast.2026.104880_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112596","article-title":"BERENICE final analysis: cardiac safety study of neoadjuvant pertuzumab, trastuzumab, and chemotherapy followed by adjuvant pertuzumab and trastuzumab in HER2-positive early breast cancer","volume":"14","author":"Dang","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/cancers15010207","article-title":"Evaluating cardiotoxicity in breast cancer patients treated with HER2 inhibitors: could a combination of radionuclide ventriculography and cardiac biomarkers predict the cardiac impact?","volume":"15","author":"Gherghe","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2026.104880_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1396133","article-title":"GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy","volume":"15","author":"Tian","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.breast.2026.104880_bib61","doi-asserted-by":"crossref","first-page":"742","DOI":"10.21037\/gs-22-161","article-title":"Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial","volume":"11","author":"Wang","year":"2022","journal-title":"Gland Surg"},{"issue":"7","key":"10.1016\/j.breast.2026.104880_bib62","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/jamacardio.2023.1229","article-title":"Association of circulating cardiomyocyte cell-free DNA with cancer therapy\u2013related cardiac dysfunction in patients undergoing treatment for ERBB2-Positive breast cancer","volume":"8","author":"Anthony","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.breast.2026.104880_bib63","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2014.58.7782","article-title":"Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo) adjuvant therapy for human epidermal growth factor receptor 2\u2013positive early-stage breast cancer","volume":"33","author":"Krop","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104880_bib64","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdr294","article-title":"Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab","volume":"23","author":"Lenihan","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104880_bib65","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10549-020-05709-z","article-title":"N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer","volume":"182","author":"Leon-Ferre","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.breast.2026.104880_bib66","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jgo.2021.02.020","article-title":"Phase II study of neratinib in older adults with HER2 amplified or HER2\/3 mutated metastatic breast cancer","volume":"12","author":"Yuan","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104880_bib67","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-020-06053-y","article-title":"Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function","volume":"185","author":"Khoury","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.breast.2026.104880_bib68","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.breast.2026.104880_bib69","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1470-2045(25)00140-8","article-title":"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study","volume":"26","author":"Escriv\u00e1-de-Romani","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib70","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13058-016-0773-6","article-title":"Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET cohort 1 final results","volume":"18","author":"Perez","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2026.104880_bib71","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10549-021-06145-3","article-title":"Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: final analysis of MetaPHER, a phase IIIb single-arm safety study","volume":"187","author":"Kuemmel","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib72","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41747-023-00338-9","article-title":"Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy","volume":"7","author":"Cheng","year":"2023","journal-title":"Eur Radiol Exp"},{"issue":"12","key":"10.1016\/j.breast.2026.104880_bib73","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.breast.2026.104880_bib74","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2021.06.024","article-title":"Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104880_bib75","doi-asserted-by":"crossref","first-page":"v98","DOI":"10.1093\/annonc\/mdx365.059","article-title":"Detection of early cardiac effects of docetaxel plus trastuzumab and pertuzumab through strain rate imaging in patients with HER2-positive metastatic breast cancer","volume":"28","author":"Michalaki","year":"2017","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.breast.2026.104880_bib76","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib77","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"10.1016\/j.breast.2026.104880_bib78","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","article-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"60","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.breast.2026.104880_bib79","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-018-5058-6","article-title":"A real-world study of cardiac events in> 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study","volume":"174","author":"Lidbrink","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2026.104880_bib81","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-017-4362-x","article-title":"Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer","volume":"166","author":"Yu","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"31","key":"10.1016\/j.breast.2026.104880_bib82","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104880_bib83","first-page":"1717","article-title":"Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer","volume":"33","author":"Naumann","year":"2013","journal-title":"Anticancer Res"},{"issue":"25","key":"10.1016\/j.breast.2026.104880_bib84","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:29:30Z","timestamp":1789612170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":84,"alternative-id":["S0960977626001906"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104880","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiotoxicity of newer HER2-Directed therapies in breast cancer: A systematic review and meta-analysis of incidence and comparative risk","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104880"}}